At 9.6x forward earnings and a 6.3% dividend yield, Pfizer trades cheaper than every large-cap pharma peer while the base business — excluding COVID — has grown 29% since 2021.
Pfizer's revenue trajectory tells a story the market has already priced in — and then some. From $81.3 billion at the COVID peak to $62.6 billion in FY2025, the top line has contracted by 23%. But here is what that chart misses: strip out COVID products entirely, and Pfizer's base business has grown from $42 billion to $54 billion over the same period. The market is punishing the company for losing COVID revenue while ignoring the fact that the underlying franchise is larger and more diversified than it was pre-pandemic.
Pfizer paid $43 billion for Seagen in late 2023, and the oncology pipeline it acquired is now the engine of the base business recovery. Padcev (bladder cancer) and Adcetris (lymphoma) are both blockbusters, and three additional antibody-drug conjugates are in late-stage development.
TickerXray Report
Get the complete Pfizer report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
At 6.3% dividend yield, Pfizer offers more income than the 10-year Treasury, most REITs, and every utility in the S&P 500. The dividend is covered by $9.1 billion in free cash flow against roughly $5.6 billion in annual dividend payments — a 61% payout ratio that leaves room for debt reduction and selective buybacks. The 15 Hold-rated analysts and 2 Buy ratings suggest the market views Pfizer as dead money. We think that consensus is about to shift.
At 9.6x forward earnings, Pfizer is cheaper than every pharmaceutical company in its peer group. Johnson & Johnson trades at 14x. Merck at 12x. AbbVie at 13x. Bristol-Myers at 8x — and Bristol has a far worse pipeline. Pfizer at 9.6x implies the market expects earnings to decline further. The consensus estimate calls for $3.20 in EPS this year, rising to $3.50 in FY2027. If those estimates are even directionally correct, Pfizer at 9.6x forward is pricing in a 15-20% earnings miss that the pipeline doesn't support.
Every chart in this analysis tells the same story: Pfizer's post-COVID adjustment is complete, the base business is growing, margins are recovering, free cash flow covers the dividend with room to spare, and the forward PE is the cheapest in the large-cap pharma peer group. The consensus target of $28.58 implies 15-20% upside plus a 6.3% yield. We see fair value closer to $32-35, which implies 30-40% total return including dividends over the next 12 months. For income-oriented investors, this is the best risk-adjusted yield in the market.
Full forensic analysis of Pfizer
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Pfizer's revenue has halved from its pandemic peak, but the oncology pipeline — anchored by a $43 billion Seagen acquisition — is the most ambitious portfolio rebuild in pharma history.
ConocoPhillips, Schlumberger, and Chevron each offer a different angle on the Hormuz thesis: pure-play E&P leverage, oilfield services recovery, and integrated yield defence. All three trade below historical averages.
PG at 21.5x earnings versus KO at 25.5x — both are Dividend Aristocrats, both own irreplaceable brands, but one offers meaningfully better value on a risk-adjusted basis. Head-to-head across five dimensions.